Roche moved to deepen its obesity pipeline by paying up to $2.3 billion to license Hanmi Pharm’s early-stage muscle-building asset targeting obesity, according to deal reporting that specifies a $190 million upfront component. The agreement centers on a non-incretin obesity drug described as a urocortin-2 analog. For Roche, it adds another mechanism to a portfolio that already includes multiple obesity collaborations, positioning the company to compete across both incretin-based and differentiated pathways. For Hanmi, the transaction provides clinical and commercial optionality as the molecule progresses, while underscoring how obesity remains a high-priority category for late-stage partners seeking differentiated MoA.